Silencing of the COPS3 gene by siRNA reduces proliferation of lung cancer cells most likely via induction of cell cycle arrest and apoptosis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 3, 2012, Pages 1043-1048

  Wang, Xue Mei ^a,c   Cui, Jiu Wei ^a   Li, Wei ^a   Cai, Lu ^a,b   Song, Wei ^a   Wang, Guan Jun ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b Jilin Province People's Hospital   (China)

^c University of Louisville School of Medicine   (United States)

Author keywords

Apoptosis; Cell cycle arrest; Cell proliferation; COPS3; Lung cancer

Indexed keywords

COPS3 PROTEIN, HUMAN; ONCOPROTEIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CELL STRAIN HEK293; GENETICS; HUMAN; LUNG TUMOR; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84871679186     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.3.1043     Document Type: Article

References (17)

1. Bech-Otschir D, Kraft R, Huang X, et al (2001). COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J, 20, 1630-9.
2. Broker LE, Giaccone G (2002). The role of new agents in the treatment of non-small cell lung cancer. Eur J Cancer, 38, 2347-61.
3. Chen L, Liang Z, Tian Q, et al (2011). Overexpression of LCMR1 is significantly associated with clinical stage in human NSCLC. J Exp Clin Cancer Res, 30, 18.
4. Devi G R (2006). siRNA-based approaches in cancer therapy. Cancer Gene Ther, 13, 819-29.
5. Fuchs B, Pritchard DJ (2002). Etiology of osteosarcoma. Clin Orthop, 397, 40-52.
6. Gokgoz N, Wunder JS, Mousses S, et al (2001). Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. Cancer, 92, 2181-9.
7. Henriksen J, Aagesen TH, Maelandsmo GM, et al (2003). Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation. Oncogene, 22, 5358-61.
8. Luo J, Emanuele MJ, Li D, et al (2009). A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell, 137, 835-48.
9. Paddison PJ, Hannon GJ (2003). siRNAs and shRNAs: skeleton keys to the human genome. Curr Opin Mol Ther, 5, 217-24.
10. Sharma SV, Bell DW, Settleman J, Haber DA (2007). Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, 7, 169-81.
11. Singh A, Boldin-Adamsky S, Thimmulappa RK, et al (2008). RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res, 68, 7975-84.
12. Skrzypski M, Dziadziuszko R, Jassem J (2011). MicroRNA in lung cancer diagnostics and treatment. Mutat Res, 17, 25-31.
13. van Dartel M, Redeker S, Bras J, Kool M, Hulsebos TJ (2004). Overexpression through amplification of genes in chromosome region 17p11.2 approximately p12 in high-grade osteosarcoma. Cancer Genet Cytogenet, 152, 8-14.
14. Wei N, Deng XW (2003). The COP9 signalosome. Annu Rev Cell Dev Biol, 19, 261-86.
15. Yan J, Walz K, Nakamura H, et al (2003). COP9 signalosome subunit 3 is essential for maintenance of cell proliferation in the mouse embryonic epiblast. Mol Cell Biol, 23, 6798-808.
16. Yan T, Wunder JS, Gokgoz N, et al (2007). COPS3 amplification and clinical outcome in osteosarcoma. Cancer, 109, 1870-6.
17. Yan T, Tang G, Ren T, et al (2011). RNAi-mediated COPS3 gene silencing inhibits metastasis of osteogenic sarcoma cells. Cancer Gene Ther, 18, 450-6.